The detection of K-ras mutations in colorectal cancer using the amplification-refractory mutation system

JC Fox\textsuperscript{1}, J England\textsuperscript{2}, P White\textsuperscript{1}, G Ellison\textsuperscript{1}, K Callaghan\textsuperscript{1}, NR Charlesworth\textsuperscript{1}, J Hehir\textsuperscript{1}, TL McCarthy\textsuperscript{1}, J Smith-Ravin\textsuperscript{1}, IC Talbot\textsuperscript{2}, D Snary\textsuperscript{1}, JMA Northover\textsuperscript{1}, CR Newton\textsuperscript{1} and S Little\textsuperscript{1}

\textsuperscript{1}Zeneca Diagnostics, Gaddbrook Park, Northwich, Cheshire CW8 7RA, UK; \textsuperscript{2}Imperial Cancer Research Fund, Colorectal Unit, St Mark's Hospital, Northwick Park, Harrow, Middlesex HA1 3UJ, UK; \textsuperscript{3}Imperial Cancer Research Fund, Applied Development Laboratory, Dominion House, 59 Bartholomew Close, St Bartholomew's Hospital, London EC1A 7BE, UK

Summary A total of 301 colorectal carcinoma (CRC) archival samples were analysed using the amplification-refractory mutation system (ARMS). Each sample was examined to determine the mutation status of codons 12 and 13 of the K-ras oncogene. The results from direct DNA sequence analysis carried out on 30 of the samples differed from the ARMS result in almost 50% of the cases as a result of the relative excess of wild-type to mutated DNA sequences. To assess the validity of the ARMS data, the polymerase chain reaction (PCR) was used to generate an amplicon from K-ras exon 1 from 23 of the samples. The PCR amplicons were cloned and sequenced, and the DNA sequence analysis of the cloned material was in agreement with the ARMS results in all but one case. This case represented a tumour that exhibited a five-nucleotide reversed inversion. The cloned sequence data confirm the sensitivity and specificity of the individual ARMS reactions and that it is possible in certain cases to detect additional, more complex, sequence variations.

Keywords: amplification-refractory mutation system; diagnosis; mutation; oncogene; screening

Colorectal cancer is the second most common malignancy in the USA (Ries et al, 1994) and is a significant cause of morbidity and mortality world-wide. The American Cancer Society estimated that in 1995 more than 130,000 new cases of CRC would be diagnosed in the USA and that there would be 54,900 deaths from the disease (American Cancer Society, 1995). CRC onset and its progression has been studied extensively at the molecular (Bos et al, 1987; Forrester et al, 1987; Vogelstein et al, 1988; Burmer and Loeb, 1989; Delattre et al, 1989; Delattre et al, 1989; Kern et al, 1989; Vogelstein et al, 1989; Fearon and Vogelstein, 1990; El-Deiry et al, 1991; Oudejans et al, 1991; Houlston et al, 1992; Laurent-Puig et al, 1992; Offerhaus et al, 1992; Sharrard et al, 1992; Bell et al, 1993; Finkelstein et al, 1993a and b; McLellan et al, 1993; Urosevic et al, 1993; Breivik et al, 1994; Dix et al, 1994; Moerkink et al, 1994; Mortin et al, 1994; Tanaka et al, 1994; Giairetti et al, 1995; Laird et al, 1995; Span et al, 1996), and genetic (Woof et al, 1958; Macklin et al, 1960; Houlston et al, 1992; Zhao and Le Marchand, 1992; Peltomaki et al, 1993; Goldgar et al, 1994; Lewis et al, 1996) levels and there is a commonly accepted model relating tumour grade according to Dukes' stage (Dukes, 1932) to specific DNA changes (Fearon and Vogelstein, 1990).

It has recently been concluded that reliable CRC screening procedures require development and that additional research is needed to identify mutated genes in blood and stool (Young and Levin, 1996). Although there are many examples of nucleic acid changes having potential as tumour markers (Bo et al, 1987; Forrester et al, 1987; Vogelstein et al, 1988; Burmer and Loeb, 1989; Delattre et al, 1989; Kern et al, 1989; Vogelstein et al, 1989; Fearon and Vogelstein, 1990; Jones and Buckley, 1990; Capella et al, 1991; Delattre et al, 1991; Oudejans et al, 1991; Stork et al, 1991; Laurent-Puig et al, 1992; Offerhaus et al, 1992; Sharrard et al, 1992; Bell et al, 1993; Finkelstein et al, 1993a and b; McLellan et al, 1993; Urosevic et al, 1993; Breivik et al, 1994; Dix et al, 1994; Magewu and Jones, 1994; Moerkink et al, 1994; Mortin et al, 1994; Tanaka et al, 1994; Giairetti et al, 1995; Laird et al, 1995; Span et al, 1996), their value as clinical tools in cancer diagnosis, staging or even screening needs to be demonstrated and two important criteria must be met. First, adequate supplies of nucleic acid must be extracted from the clinical material; second, robust and accurate methods of analysis are required. For reliable tumour genotyping to be useful in disease staging, any test has to be adequately validated and there should be demonstrable benefits over current methods.

A significant proportion of CRCs have mutations in the K-ras oncogene (Bo et al, 1987; Forrester et al, 1987; Vogelstein et al, 1988; Burmer and Loeb, 1989; Delattre et al, 1989; Fearon and Vogelstein, 1990; Capella et al, 1991; Oudejans et al, 1991; Offerhaus et al, 1992; Bell et al, 1993; Finkelstein et al, 1993a and b; McLellan et al, 1993; Urosevic et al, 1993; Breivik et al, 1994; Moerkink et al, 1994; Mortin et al, 1994; Tanaka et al, 1994; Giairetti et al, 1995; Laird et al, 1995; Span et al, 1996). We report a study using 301 DNA samples extracted from a colorectal tumour bank. In this study, mutations within codons 12 and 13 of the K-ras oncogene were investigated using amplification-refractory mutation system (ARMS) (Newton et al, 1989). Direct DNA sequencing (Newton et al, 1988) and sequencing of cloned amplicons were then performed to assess the ARMS test results. In almost half of the cases, the direct sequencing result detected K-ras wild-type sequence only, this was in contrast to the ARMS
findings in which mutations in codons 12 and 13 were detected. However, when K-ras exon 1 amplicons were cloned into *Escherichia coli*, the ARMS result was consistently in accord with the sequence of the cloned material, with the exception of one tumour that harboured a mutation of five consecutive nucleotides, which was detected by three of the ARMS primers. Our data show that ARMS is a sensitive test for detecting under-represented nucleic acid sequences. We also demonstrate that the technique is ideally suited to the detection of tumour DNA markers supplying genotype information specific to prediagnosed tumours.

**MATERIALS AND METHODS**

**DNA extraction from tumour bank samples**

DNA was extracted from 301 frozen tissue samples. Positive selection of samples comprised the exclusion of most adenomas and tumours from familial adenomatous polyposis patients. Altogether, the samples comprised colorectal lesions excised between January 1985 and January 1995, six of which were adenomas. Of the remaining cancers, 31 were Dukes’ stage A, 135 Dukes’ B and 129 Dukes’ C (Dukes, 1932). Each frozen specimen was sectioned by cryostat, 5 μm was taken for haematoxylin and eosin staining, three or four parallel 10-μm sections were transferred to sterile tubes and stored at −70°C. Fresh blades were used for each sample. DNA extraction comprised thawing sections on ice and the addition of sufficient sterile lysis buffer (10 mM Tris-HCl, pH 7.5, 20% sodium dodecyl sulphate, 50 μg ml−1 proteinase K) to saturate the material. After an overnight digestion at 37°C, a standard phenol–chloroform purification and ethanol precipitation was carried out (Sambrook et al, 1989). The resulting DNA was resuspended in 200 μl of 10 mM Tris-HCl (pH 7.5). DNA samples were then stored at −70°C before quantification and K-ras mutation analysis.

**K-ras mutation ARMS tests**

Individual ARMS tests were developed to detect specific point mutations in the K-ras oncogene. The 3’-terminal base of each of seven ARMS oligonucleotide primers was complementary to one of the common mutations of codons 12 or 13 of the K-ras oncogene occurring in CRCs (Breivik et al, 1994) (Figure 1). In addition to the ARMS primers, a common primer complementary to the K-ras intron sequence was included (Figure 1). Two other primer pairs were also present in each test to give amplification control products. Their sequences were: 5’-TATATGTGCGGTGGCCTGTGCAAGGAAG-3’ and 5’-CTCCTACACCCAGCCATTTTTGCC-3’, which amplify part of exon IV of the cystic fibrosis transmembrane conductance regulator (CFTR) gene (Riordan et al, 1989), and 5’-GGGCTCTAGCTCCAAACATGGCTAAGAGGTG-3’ and 5’-CCCACCTCCCTCCTCTCCAGCATAAGG-3’, which amplify a part of each of exon II and intron III of the human γ-antitrypsin gene (Newton et al, 1988).

Normal human DNA was extracted from the blood of healthy volunteers (Ferrie et al, 1992). K-ras mutated DNA samples were extracted from tumour derived cell lines as shown in Table 1. The K-ras mutation for each cell line DNA was confirmed by direct DNA sequencing as described below for tumour-derived DNA samples. The cell line DNAs were then used to define amplification conditions that conferred specificity to each ARMS reaction when the following criteria were applied. First, after the DNA amplification reaction and agarose gel electrophoresis in the presence of 0.5 μg ml−1 ethidium bromide (Sambrook et al, 1989), the test should give a visible ARMS band only when either 10th genome equivalents of the appropriate mutant DNA with 10th equivalents of normal DNA are combined or when 10th genome equivalents of mutant DNA alone is tested. (A genome equivalent meaning here the amount of genomic DNA per cell.) In addition, there should be no visible ARMS product from any primer when 10th genome equivalents of normal DNA is tested in isolation. The annealing temperature and number of cycles used for each ARMS reaction is shown in Table 2. All amplification reactions were performed applying the commonly accepted precautions for avoiding carry-over contamination (Kwok and Higuchi, 1989).

The amount of DNA extracted from each tumour sample was measured by fluorescence after intercalation of the Hoechst 33258 dye (Riley et al, 1989). ARMS reactions containing these DNAs (1 μl each) were performed in 50 μl of buffer comprising 10 mM Tris-HCl, pH 8.3, 1.2 mM magnesium chloride, 50 mM potassium chloride, 0.01% gelatin and dNTPs (100 μM each). The reactions also contained mutation-specific and the appropriate intron-specific primers (1 μM each) as shown in Figure 1. The CFTR gene amplimers were 0.075 μM each and the α,β-antitrypsin primers were 0.025 μM each. Hot-start PCR (D’Aquila et al, 1991; Chou et al, 1992) was performed throughout by adding a layer of
white mineral oil and heating the samples at 94°C for 5 min before adding Taq DNA polymerase (1 unit). Thermal cycling comprised 35 or 36 cycles (Table 2) of 94°C, 1 min denaturation; 58–63°C, 1 min annealing (Table 2); 72°C, 1 min extension. This was followed by a final incubation at 72°C for 10 min. Any samples that failed to amplify, identified by the absence of control bands, were re-tested until data acquisition for all tumour samples with all seven tests was complete.

K-ras ARMS test validation: direct sequencing of tumour derived DNA
Tumour derived DNA (2 µl) was amplified in 50 µl reactions that comprised 10 mM Tris-HCl, pH 8.3, 100 mM tetramethylammonium chloride, 3 mM magnesium chloride, 0.05% Tween-20, 0.05% Nonidet NP40, dNTPs (200 µM each) and 2.5 units of Taq DNA polymerase. Each reaction also contained the forward primer 5’-CTGGATCTAGACTCATGAAAATGGTCAGAGAA-ACCTTTATC-3’ and the reverse primer 5’-CCTCGGAATTGGTAGCGTATTGCTGATTTAACC-3’ (500 nM each), which generate an amplicon from exon I of the K-ras oncogene with flanking XbaI and EcoRI restriction enzyme recognition sites. Reactions were overlaid with mineral oil (50 µl) and amplified over 35 cycles of 94°C, 60°C, 72°C (1 min each). After electrophoresis through a 2% metaphor agarose gel (FMC Bioproducts), the exon I bands were excised and purified using a Wizard DNA purification kit (Promega). Typical yields were 1–5 µg in 50 µl. The purified products were sequenced by direct incorporation of [α-35-S]dATP (Amersham) using a modified version (Green et al, 1989) of the Sequenase 2.0 DNA sequencing kit (Amersham). Annealing mixtures also contained template DNA (6 µl), sequencing primer (1 µl, 500 ng) and dimethyl sulphoxide (1 µl), (Sigma). Each labelling reaction was supplemented with 0.2 u of DNA polymerase I, Klenow fragment (labelling grade, Boehringer Mannheim; Redston et al, 1994). Sequencing reactions were run on 6% polyacrylamide gels that were subsequently dried and autoradiographed.

K-ras ARMS test validation: cloning and sequencing of tumour DNAs
An aliquot of each amplicon prepared for direct DNA sequencing was also ligated into the vector pGEM-T (Promega) at 17°C overnight. A 2 µl aliquot from each ligation mixture was used to transform competent Escherichia coli JM109 cells (Promega). These were plated and blue/white screened according to the supplier’s instructions. White colonies were picked into 10 ml of sterile distilled water. PCR using the conditions described above, but for 25 cycles, was carried out to test simultaneously for the presence of an insert and the K-ras mutation status of any insert. The amplifiers in each reaction were the M13 5’-GGTTTTCCAGTTCAGCAG-3’ (forward), 5’-CAGGAAACAGCTATGAAAATGGTCAGAGAA-ACCTTTATC-3’ (reverse) primers and the ARMS primer that initially identified the mutation. Amplification products were then visualized on a 3% agarose gel. Clones with inserts detected by the PCR screen were picked into 1 ml of LB broth and grown overnight at 37°C. An aliquot (100 µl) from each was inoculated into a further 1 ml of broth and grown for 3–4 h at 37°C. Ten p.f.u. per cell of M13KO7 helper phage was then added to each culture. After 1 h at room temperature, LB broth (9 ml) containing 70 mg/ml kanamycin and 100 mg/ml ampicillin was added and the culture incubated overnight at 37°C. Virus particles were isolated by polyethylene glycol 6000/sodium chloride precipitation, and single-stranded DNA was isolated by phenol–chloroform extraction followed by ethanol precipitation (Sambrook et al, 1989). DNA sequencing was performed using the M13 forward primer as described above.

RESULTS
Histological analyses
Histological examination of the haematoxylin and eosin-stained material confirmed the presence of tumour cells in at least 90% of the sample in each case (data not shown).

ARMS test development
Thermal cycling and primer annealing conditions were determined empirically, having imposed the specificity criteria described above; these are shown in Table 2. An example showing the specificity of each of four of the tests is shown in Figure 2.
Table 3  The ARMS test, direct sequencing and clone analysis results grouped according to the ARMS primer(s) found to generate K-ras amplicons

| Tumour | ARMS result | Dukes' stage | Direct DNA sequence result |
|--------|-------------|--------------|---------------------------|
| 980    | K12 Ser     | C            | K12 Ser                   |
| 982    | K12 Ser     | B            | K12 Ser                   |
| 1271   | K12 Ser     | C            | K12 Ser                   |
| 23     | K12 Cys     | C            | wt                        |
| 214    | K12 Cys     | B            | wt                        |
| 1253   | K12 Cys     | C            | wt                        |
| 1257   | K12 Cys     | A            | K12 Cys                   |
| 6      | K12 Arg     | C            | K12 Arg                   |
| 188    | K12 Val     | A            | wt                        |
| 406    | K12 Val     | B            | K12 Val                   |
| 436    | K12 Val     | B            | wt                        |
| 561    | K12 Val     | C            | K12 Val                   |
| 777    | K12 Val     | B            | wt                        |
| 1182   | K12 Val     | B            | K12 Val                   |
| 1210   | K12 Val     | A            | wt                        |
| 1261   | K12 Val     | C            | K12 Val                   |
| 1289   | K12 Val     | B            | wt                        |
| 202    | K12 Asp     | B            | wt                        |
| 328    | K12 Asp     | B            | K12 Asp                   |
| 357    | K12 Asp     | B            | K12 Asp                   |
| 565    | K12 Asp     | B            | wt                        |
| 598    | K12 Asp     | B            | K12 Asp                   |
| 734    | K12 Asp     | C            | K12 Asp                   |
| 1076   | K12 Asp     | C            | K12 Asp                   |
| 72     | K13 Asp     | C            | K13 Asp                   |
| 178    | K13 Asp     | C            | K13 Asp                   |
| 302    | K13 Asp     | C            | wt                        |
| 596    | K13 Asp     | C            | wt                        |
| 863    | K13 Asp     | B            | K13 Asp                   |
| 1342   | K12 Ser+ Arg+Ala | B | Multiple |

DNA yield from tumour extracts

The maximum and minimum DNA yield was 124.5 μg (622.5 ng μl⁻¹) and 1.5 μg (7.5 ng μl⁻¹), respectively, approximating to between 1.25x10⁶ and 1.5x10⁶ human diploid genome equivalents μl⁻¹. Six of the Dukes' C samples failed to give sufficient DNA to reach the threshold of detection, but this did not preclude ARMS analyses of these samples. In general, a lower yield of DNA was associated with the extracts from Dukes' C classified tumours. The mean DNA yield was 25.6 μg (128.0 ng μl⁻¹), approximately 2.5x10⁶ genome equivalents μl⁻¹, after discounting the six samples that failed to give measurable quantities of DNA extract.

ARMS tests and direct sequencing

A typical ARMS result is shown in Figure 3. A summary of the K-ras mutations detected using ARMS, the Dukes' stage of the tumour and the direct DNA sequencing result for 30 of the tumour DNAs examined is shown in Table 3.

Quantitative analysis of K-ras mutations

Three primer PCR results used to classify clones from a selection of tumour DNAs are shown in Figure 4. Table 4 provides an analysis of the ARMS data, direct DNA sequencing and clone analyses from equivalent samples.

K-ras mutational analysis of the 301 tumour bank samples

As the majority of CRCs were classified as either Dukes' B or C at the time of surgery, a relatively smaller number of Dukes' A (31 in
Table 4  Direct and cloned sequence results from tumour DNAs grouped according to the ARMS primer that initially characterized the K-ras mutation harbouring the tumour

| Tumour DNA | ARMS result | Direct sequence result | Frequency of mutation in clones | Sequence of ARMS-positive clones |
|------------|-------------|------------------------|---------------------------------|---------------------------------|
| 1271       | 12 Ser      | 12 Ser                 | 5 of 27 (19)                    | 12 Ser                          |
| 1342       | 12 Ser      | Unclear                | 16 of 28 (57)                  | Five mutations                   |
| 23         | 12 Cys      | wt                     | 14 of 38 (37)                  | 12 Cys                          |
| 214        | 12 Cys      | wt                     | 12 of 33 (36)                  | 12 Cys                          |
| 500        | 12 Cys      | wt                     | 10 of 33 (30)                  | 12 Cys                          |
| 530        | 12 Cys      | wt                     | 2 of 34 (6)                    | 12 Cys                          |
| 1253       | 12 Cys      | wt                     | 21 of 43 (49)                  | 12 Cys                          |
| 6          | 12 Arg      | 12 Arg                 | 4 of 10 (40)                   | 12 Arg                          |
| 957        | wt          | wt                     | 0                              | No positive clones              |
| 1342       | 12 Arg      | Unclear                | 0                              | No positive clones              |
| 1342       | 12 Ala      | Unclear                | Not done                       | Not done                        |
| 188        | 12 Val      | wt                     | 8 of 39 (21)                   | 12 Val                          |
| 436        | 12 Val      | wt                     | 11 of 33 (33)                  | 12 Val                          |
| 556        | 12 Val      | 12 Val                 | 12 of 37 (32)                  | 12 Val                          |
| 777        | 12 Val      | 12 Val                 | 4 of 38 (10)                   | 12 Val                          |
| 1210       | 12 Val      | wt                     | 3 of 42 (7)                    | 12 Val                          |
| 1289       | 12 Val      | 12 Val                 | 10 of 38 (26)                  | 12 Val                          |
| 177        | 12 Asp      | wt                     | 15 of 41 (37)                  | 12 Asp                          |
| 202        | 12 Asp      | wt                     | 2 of 12 (21)                   | 12 Asp                          |
| 357        | 12 Asp      | 12 Asp                 | 20 of 41 (49)                  | 12 Asp                          |
| 410        | 12 Asp      | wt                     | 7 of 37 (19)                   | 12 Asp                          |
| 546        | 12 Asp      | wt                     | 3 of 39 (8)                    | 12 Asp                          |
| 565        | 12 Asp      | wt                     | 2 of 34 (6)                    | 12 Asp                          |
| 302        | 13 Asp      | wt                     | 4 of 41 (10)                   | 13 Asp                          |
| 596        | 13 Asp      | wt                     | 5 of 24 (21)                   | 13 Asp                          |

*Numbers in parentheses are percentages.

Table 5  Analysis of the frequencies of the K-ras mutations detected using ARMS from all samples from the CRC tumour bank

| Tumour     | Frequencies (male patients) | Frequencies (female patients) | Frequencies (all patients) |
|------------|-----------------------------|-------------------------------|-----------------------------|
|            | K-ras positive | K-ras negative | K-ras positive | K-ras negative | K-ras positive | K-ras negative |
| Adenoma    | 1 of 4 (25%)  | 3 of 4 (75%)  | 0 of 2 (0)    | 2 of 2 (100) | 1 of 6 (17)   | 5 of 6 (83%)   |
| Dukes’ A   | 5 of 15 (33%) | 10 of 15 (67%) | 8 of 16 (50) | 8 of 16 (50) | 13 of 31 (42) | 18 of 31 (58)  |
| Dukes’ B   | 24 of 74 (32%) | 50 of 74 (68%) | 23 of 61 (38) | 38 of 61 (62) | 47 of 135 (35) | 88 of 135 (65) |
| Dukes’ C   | 28 of 90 (31%) | 62 of 90 (69%) | 20 of 39 (51) | 19 of 39 (49) | 48 of 129 (37) | 81 of 129 (63) |

*Numbers in parentheses are percentages.

total, 10.3%) cancers were analysed. There were six adenomas in total (2%) for the same reason and also because of the deliberate selection against these. In the 295 tumours, there were more from male than female patients (183 male, 118 female); 36% had K-ras mutations and there were relatively higher numbers of severe disease patients: 31, 135 and 129 Dukes’ stages A, B and C respectively. There were relatively more severe male than female patients (male–female ratio for each Dukes’ stage is A, 15:16; B, 74:61; C, 90:39; P < 0.05). For the proportion of K-ras mutations, there was evidence that this was less (P < 0.05) for men (31.7%) than for women (43.2%). There was no evidence that the proportions differed across Dukes’ stages either for the sexes separately or combined (combined proportions, Dukes’ A, 13:18, 42%; Dukes’ B, 47:88, 35%; and Dukes’ C 48:81, 37%; P > 0.05). Table 5 shows the results based on which the K-ras codons 12 and 13 mutational analysis was made and the relative K-ras mutation frequencies.

**DISCUSSION**

Many studies have examined the association of K-ras mutations with CRC (Bos et al, 1987; Forrester et al, 1987; Vogelstein et al, 1988; Bos, 1989; Burmer and Loeb, 1989; Vogelstein et al, 1989; Capella et al, 1991; Oudejans et al, 1991; Sidransky et al, 1992; Bell et al, 1993; Finkelstein et al, 1993a and b; McLellan et al, 1993; Urosevic et al, 1993; Breivik et al, 1994; Moerkerk et al, 1994; Morrin et al, 1994; Giaretti et al, 1995; Hasegawa et al, 1995; Hayashi et al, 1995; Ranaldi et al, 1995; Carpenter et al,
1996; Span et al, 1996; Villa et al, 1996). However, there are significant differences in reported frequencies of K-ras mutations in CRC (McLellan et al, 1993). Inconsistencies between studies could be due to one or more of several factors. These include the number of tumours investigated, the methods used and the number of individual point mutations tested for. It is therefore difficult to state the true number of CRCs that contain K-ras mutations.

The aims of our study were to develop validated tests for seven K-ras point mutations and to apply them in a thorough investigation of the incidence of the mutations in tumours from a large cohort of CRC patients. As part of the ARMS test validation process we used the sequencing strategy described in Materials and methods. Our initial approach to directly sequence PCR amplicons verified the ARMS result in approximately half of the tumour DNA samples investigated. One possible explanation for this could be that the ARMS tests failed to discriminate mutated from normal sequences. The tumours were not microdissected. However, a large proportion of tumour cells relative to normal tissue was identified by histology. Assuming that the tumour cells were monoclonal for any given K-ras mutation, the ratio of mutant to normal DNA might then be expected to be relatively high. K-ras is an oncogene, thus there is no reason to suppose that the normal copy of the gene should not be present in K-ras mutant tumour cells, unlike in the occurrence of allele loss with tumour-suppressor genes (Kern et al, 1989; Vogelstein et al, 1989; Fearon and Vogelstein, 1990). Therefore, when taking into account the presence of normal DNA, the mutant sequences could actually be expected to account for only a small proportion of the total DNA of the sample and so go undetected by direct DNA sequencing. This is upheld by our observations, and we therefore concluded that direct DNA sequencing was inappropriate for substantiating the ARMS results. This was confirmed by the second stage of validation in which cloned amplicons of K-ras exon 1 were sequenced. Here, the DNA sequence data gave similar results to those derived by ARMS. The results from this stage of validation therefore indicate the use of a method that will detect mutations that are under-represented against a background of wild-type alleles. The ARMS tests described herein were validated to a sensitivity of at least one mutant ras sequence in 10^5 wild-type sequences. In fact, control reactions for tumour DNA analysis had routinely lower ratios of mutant to wild-type input DNA. Other groups (Ehlen and Dubeau, 1989; Stork et al, 1991; Cha et al, 1992; Hasegawa et al, 1995; Hayashi et al, 1995; Carpenter et al, 1996) have reported tests based on the same principles as the ARMS tests described here. Detection levels of mutant ras sequences present at as low as 1 in 10^3 wild-type sequences have been reported (Ehlen and Dubeau, 1989; Cha et al, 1992) and 1 in 10^3 (this study and Carpenter et al, 1996). This ability of the technique to detect rare mutations in a background of normal DNA demonstrates its potential role in screening or in the monitoring of residual disease.

ARMS is a simple and accurate method and has several benefits over other PCR-based mutation detection systems. Specifically, the technique does not require the use of radioisotopes or the multiple probing of immobilized PCR amplicons (McLellan et al, 1993; Breivik et al, 1994; Villa et al, 1996) or cloned PCR amplicons (Sidransky et al, 1992). The technique avoids the DNA sequencing of single-strand conformation polymorphism products (Span et al, 1996), a technique that could be expected to be constrained by sequence under-representation as discussed above. Similarly, under-represented mutant sequences could go undetected using PCR in conjunction with restriction fragment length polymorphism (Chen and Viola, 1991), which is limited to low cycle numbers for the PCR to avoid false-positive results. ARMS can be performed such that carry-over contamination is avoided (Kwok and Higuchi, 1989), as it was in the study presented herein. There is a severe limitation of the studies that have examined the elimination of the BstNI restriction site at codon 12 in some K-ras mutations (Levi et al, 1991; Carpenter et al, 1996). This is because these tests rely on a BstNI restriction digest part way through PCR cycling. Previously generated amplicons therefore have the potential to cause carry-over contamination when PCR is resumed. In effect, it is not possible to keep PCR set-up and PCR analysis separated, a major drawback in the clinical setting.

One DNA sample analysed gave a positive result in more than one ARMS test. Sample 1342 was derived from a Dukes’ B rectal tumour from a 49-year-old man. This sample gave a positive result with the K12 glycine (GTT) to arginine (CGT), serine (AGT) and alanine (GCT) tests. Direct sequence analysis was non-informative but DNA sequencing of each of the cloned PCR amplicons revealed a five-nucleotide mutation. The normal sequence for codons 11–13 (GCT GGT GGC) was changed to GCC ACC AGC such that there is a reversed inversion of the last nucleotide of codon 11 to the first nucleotide of codon 13, resulting in a K12 glycine to threonine and K13 glycine to serine mutant protein. Such an occurrence could possibly be the result of an aberrant recombination event. The DNA sequencing results therefore exclude the possibility that tumour 1342 is polyclonal for more than one K-ras point mutation. None of the tumours analysed were found to have more than one K-ras mutation, also the overall frequency of K-ras mutation did not increase significantly between Dukes’ stages. This supports the model that K-ras mutation is a relatively early event in the progression of CRC through Dukes’ stages A to C (Fearon and Vogelstein, 1990). Because only six adenomas were included in this study, the exact timing of K-ras mutation in the adenoma to carcinoma progression was not addressed.

The value of K-ras mutations as a marker of malignancy will depend on several factors, not least being the frequency of tumours of a given tumour type, such as CRC, that carry the mutation. As this study has found the frequency of K-ras mutation to be approaching 40%, additional markers for CRC would be required for general screening purposes if all CRCs were to be identified using ARMS. Tumour genotyping tests can be used for disease staging (Hayashi et al, 1995). However, the value of tumour genotyping for screening for CRC by the identification of DNA changes is unknown. Studies have begun to address the clinical significance of DNA testing (Oudejans et al, 1991; Sidransky et al, 1992; Bell et al, 1993; Finkelstein et al, 1993a; Hasegawa et al, 1995; Hayashi et al, 1995; Petersen, 1995; Ranaldi et al, 1995; Span et al, 1996; Villa et al, 1996). The ARMS tests described herein have been applied for clinical purposes. The significance and the findings of these studies will be published separately.

ABBREVIATIONS
ARMS, amplification-refractory mutation system; CFTR, cystic fibrosis transmembrane conductance regulator; CRC, colorectal cancer; PCR, polymerase chain reaction; p.f.u., plaque-forming units

ACKNOWLEDGEMENTS
The PCR process is covered by patents held by F Hoffmann–La Roche. ARMS is a trade mark of Zeneca Limited. The ARMS
Goldgar patent

Dix and BosJL,Fearon ER, Bos Delattre K-ras-2 mutation analysis. Biochem J 1991 Cell reaction Salmon stages J WS, K, Almoguera C, human assay of K-ras cancer. Proc Natl Acad Sci U S A 1990 ras site mutation of K-ras Val-12 mutation in colorectal cancer as detected with sensitive methods. Clin Chem 42: 904–909

Cha RS, Zarbl H, Keohavong P and Thilly W (1992) Mismatch amplification mutation assay (MAMA): application to the h-ras gene. PCR Method Appl 2: 16–20

Chen J and Viola MV (1991) A method to detect ras point mutations in small subpopulations of cells. Anat Biochem 195: 51–56

Chou Q, Russell M, Birch DE, Raymond J and Bloch W (1992) Prevention of pre-PCR mis-primer and primer dimerization improves low-copy-number amplifications. Nucleic Acid Res 20: 1717–1723

D’Aquila RT, Bechtel LJ, Vieder JA, Eron JT, Goczypa P and Kaplan JC (1991) Maximizing sensitivity and specificity of PCR by pre-amplification heating. Nucl Acid Res 19: 3749

Delattre O, Law DJ, Remvikos Y, Sastre X, Feinberg AP, Olschswag S, Melot T, Salmon RJ, Validire P and Thomas G (1989) Multiple genetic alterations in distal and proximal colorectal cancer. Lancet 2: 353–356

Dis BR, Robbins P, Soong R, Jenner D, House AK and Lacopetta B (1994) The common molecular genetic alterations in Dukes’ B and C colorectal carcinomas are not short-term prognostic indicators of survival. Int J Cancer 59: 747–751

Dukes CE (1932) The classification of the cancer of the rectum. J Pathol Bacteriol 35: 323–332

Ehlen T and Dubeau L (1989) Detection of ras point mutations by polymerase chain reaction using mutation-specific insinuating containing oligonucleotide primers. Biochem Biophys Res Commun 160: 441–447

El-Deiry WS, Nelkin BD, Celano F, Yen RW, Falco JP, Hamilton SR and Baylin SB (1991) High expression of the DNA methyltransferase gene characterizes human neuroblastoma cells and progression stages of colon cancer. Proc Natl Acad Sci U S A 88: 3470–3474

Fearon ER and Vogelstein B (1990) A genetic model for colorectal tumorigenesis. Cell 64: 759–767

Ferrie RM, Schwartz MJ, Robertson NH, Vaudin S, Super M, Malone G and Little S (1972) Development, multiplexing and application of ARMS tests for common mutations in the CFTR gene. Am J Hum Genet 51: 251–262

Finkelstein SD, Sayegh R, Bakker A, Swaisky P and Steele GD (1993a) Determination of tumor aggressiveness in colorectal cancer by K-ras-2 analysis. Arch Surg 128: 526–532

Finkelstein SD, Sayegh R, Christensen S and Swalsky PA (1993b) Genotypic classification of colorectal adenocarcinoma–biologic behaviour correlates with K-ras-2 mutation type. Cancer 71: 3827–3838

Forrester K, Almoguera C, Han K, Grizzle WE and Perucchi M (1987) Detection of high incidence of K-ras oncoproteins during human colon tumorigenesis. Nature 327: 298–303

Giaietti W, Pujic N, Rapallo A, Nigro S, Di Vinci A, Geido E and Risiio M (1995) K-ras G:C and G:T transitions correlate with DNA aneuploidy in colorectal adenomas. Gastroenterology 108: 1040–1047

Goldgar DE, Easton DF, Cannon-Albright LA and Skolnick MH (1994) Systematic population-based assessment of cancer risk in first-degree relatives of cancer probands. J Natl Cancer Inst 86: 1600–1608

Green PM, Bentley DR, Mihebohan RS, Nilsson IG and Giannelli F (1989) Molecular pathology of Haemophilus B. EMBO J 8: 1067–1072

Hasegawa Y, Takada S, Ichii S, Koizumi K, Maruyama M, Fujii A, Ohita H, Nakajima T, Okuda M, Baba S and Nakamura Y (1995) Detection of K-ras mutations in DNAs isolated from feces of patients with colorectal tumors by mutant-allele-specific amplification (MASA) Oncogene 10: 1441–1445

Hayashi N, Ito Y, Yanagisawa A, Kato Y, Nakamori S, Imaoka S, Watanabe H, Ogawa M and Nakamura Y (1995) Genetic diagnosis of lymph-node metastasis in colorectal cancer. Lancet 345: 1257–1259

Houlston RS, Collins A, Stack J and Morton NE (1992) Dominant genes for colorectal cancer are not rare. Ann Hum Genet 56: 99–103

Jones PA and Buckley JD (1990) The role of DNA methylation in cancer. Adv Cancer Res 54: 1–23

Kern SE, Fearon ER, Tersmette KWF, Enterline JP, Leppert M, Nakamura Y, White R, Vogelstein B and Hamilton SR (1989) Allelic loss in colorectal carcinoma. J Am Med Assoc 261: 3099–3103

Kwok S and Heguchi R (1989) Avoiding false positives with PCR. Nature 339: 237–238

Laird PW, Jacksonslyuth F, Fazeli A, Dickson SL, Jung WE, Li E, Weinberg RA and Jaenisch R (1995) Suppression of intestinal neoplasia by DNA hypomethylation. Cell 81: 197–205

Laurent-Piquet P, Olschwang S, Delattre O, Remvikos Y, Assellain B, Melot T, Validire P, Mulleris M, Giros I, Salmon RJ and Thomas G (1992) Survival and acquired genetic alterations in colorectal cancer. Gastroenterology 102: 1136–1141

Levi S, Urbano-Ispizua A, Gill R, Thomas DM, Gilbertson J, Foster C and Marshall CJ (1991) Multiple K-ras codons 12 mutations in cholangiocarcinomas demonstrated with a sensitive polymerase chain reaction technique. Cancer Res 51: 3497–3502

Lewis CJ, Neuhass DD, Black FJ, Swenssen J, Burt RW, Cannon-Albright LA and Skolnick MH (1996) Genetic heterogeneity and unmapped genes for colorectal cancer. Cancer Res 56: 1382–1388

Macklin MT (1960) Inheritance of cancer of the stomach and large intestine in man. J Natl Cancer Inst 24: 551–571

Magewa AN and Jones PA (1994) Ubiquitous and tenacious methylation of the CpG site in codon-248 of the p53 gene may explain its frequent appearance as a mutational hot-spot in human cancer. Mol Cell Biol 14: 4225–4232

McEllean EA, Owen RA, Stepniewska KA, Sheffield JP and Lemoine NR (1993) High frequency of K-ras mutations in sporadic colorectal adenomas. Gut 34: 396–396

Moerkerk P, Arends JW, Van Driel M, De Bruine A, De Goey A and Ten Kate J (1994) Type and number of K-ras point mutations relate to stage of human colorectal cancer. Cancer Res 54: 3376–3378

Morin M, Kelly M, Barrett N and Delaney P (1994) Mutations of K-ras and p53 genes in colorectal cancer and their prognostic significance. Gut 35: 1627–1631

Newton CR, Kalshaker N, Graham A, Powell S, Gammack A, Riley J and Markham AF (1988) Diagnosis of a G,A antipyrin deficiency by enzymatic amplification of human genomic DNA and direct sequencing of polymerase chain reaction products. Nucleic Acid Res 16: 8233–8243

Newton CR, Graham A, Hewstall LE, Powell SJ, Summers C, Kalshaker N, Smith JC and Markham AF (1989) Analysis of any point mutation in DNA. The amplification refractory mutation system (ARMS). Nucleic Acid Res 17: 2503–2516

Offerhaus GJA, De Feyter EP, Cornelisse CJ, Tersmette KWF, Floyd J, Kern SE, Vogelstein B and Hamilton SR (1992) The relationship of DNA aneuploidy to molecular genetic alterations in colorectal carcinoma. Gastroenterology 102: 1612–1619

Oudejans JJ, Slabos RJC, Zoetemelker FAN, Mooi WI and Rodenhuis S (1991) Differential activation of ras genes by point mutation in human colon cancer with metastases to either lung or liver. Int J Cancer 49: 875–879

Pelomskii P, Aaltone LA, Sistone P, Pylkkanele L, Mecklin J-P, Jarvinen H, Green JS, Jass JR, Weber JL, Leach JL, Leach FS, Petersen GM, Hamilton SR, Del La Chapelle A and Vogelstein B (1993) Genetic mapping of a locus predisposing to human colorectal cancer. Science 260: 810–812

Petersen GM (1995) Genetic epidemiology of colorectal cancer. Eur J Cancer 31A: 1047–1050

Ranaldi R, Giocchin AM, Manzin A, Clementi M, Stefania P and Bazzari I (1995) Adenoma–carcinoma sequence of colorectum. Diagn Mol Pathol 4: 198–202

Redston MS and Kern SE (1994) Klenow co-sequencing: a method for eliminating ‘spots’. Biotechniques 17: 286–288

Ries LAG, Miller BA, Hankey BF, Kosary CL, Harras A and Edwards BK (1994) Surveillance, Epidemiology and End Results (SEER) Cancer Statistics Review, 1973–1991: Tables and Graphs. National Cancer Institute. NIH publication no. 94–2789. Bethesda, USA

© Cancer Research Campaign 1998

British Journal of Cancer (1998) 77(8), 1267–1274

ARMS analysis of K-ras in colorectal cancer 1273
Riley J, Jenner D, Smith JC and Markham AF (1989) Rapid determination of DNA concentration in multiple samples. Nucleic Acid Res 17: 8383

Riordan JR, Rommens JM, Kerem B, Alon N, Rozmahel R, Grzelczak Z, Zielinski J, Lok S, Plavsic N, Chou J, Drumm MJ, Ianuzzi MC, Collins FS and Tsui L (1989) Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 245: 1066–1073

Sambrook J, Fritsch EF and Maniatis T (1989) Molecular Cloning: A Laboratory Manual. 2nd edn. Cold Spring Harbor Laboratory Press: Cold Spring Harbor, NY

Sharrard RM, Royds JA, Rogers S and Shorthouse AJ (1992) Patterns of methylation of the c-myc gene in human colorectal cancer progression. Br J Cancer 65: 667–672

Sidransky D, Tokino T, Hamilton SR, Kinzler KK, Levin B, Frost P and Vogelstein B (1992) Identification of ras oncogene mutations in the stool of patients with curable colorectal tumors. Science 256: 102–105

Span M, Moerker PTM, De Goeij AFPM and Arends JW (1996) A detailed analysis of K-ras mutations in relation to tumor progression and survival in colorectal cancer patients. Int J Cancer 69: 241–245

Stork P, Loda M, Bosari S, Wiley B, Poppenhusen K and Wolfe H (1991) Detection of K-ras mutations in pancreatic and hepatic neoplasms by non-isotopic mismatched polymerase chain reaction. Oncogene 6: 857–862

Tanaka M, Omura K, Watanabe Y, Oda Y and Nakaniishi I (1994) Prognostic factors of colorectal cancer: K-ras mutation, overexpression of the p53 protein, and cell proliferative activity. J Surg Oncol 57: 57–64

Urosevic N, Krtolica K, Scaro-Milic A, Knezevic-Usai S and Dujic A (1993) Prevalence of G-to-T transversions among K-ras oncogene mutations in human colorectal cancer in Yugoslavia. Int J Cancer 54: 249–254

Villa E, Dugani A, Rebecchi AM, Vignoli A, Grotolila A, Buttafoco P, Losi L, Perini M, Trande P, Merighi A, Lerose R and Manenti F (1996) Identification of subjects at risk for colorectal carcinoma through a test based on K-ras determination in the stool. Gastroenterology 110: 1346–1353

Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, Nakamura Y, White R, Smits AMM and Bos JL (1988) Genetic alterations during colorectal tumor development. N Engl J Med 319: 525–532

Vogelstein B, Fearon ER, Kern SE, Hamilton SR, Preisinger AC, Nakamura Y and White R (1989) Allelotype of colorectal carcinomas. Science 244: 207–211

Woolf CM (1958) A genetic study of carcinoma of the large intestine. Am J Hum Genet 10: 42–47

Yamada H, Yoshida T, Sakamoto H, Terada M and Sugimura T (1986) Establishment of a human pancreatic adenocarcinoma cell line (PSN-1) with amplifications of both c-myc and activated c-Ki-ras by a point mutation. Biochem Biophys Res Commun 140: 167–173

Young G and Levin B (1996) Report of UICC colorectal cancer screening workshop. Int J Cancer 65: 567–568

Zhao LP and Le Marchand L (1992) An analytical method for assessing patterns of familial aggregation in case–control studies. Genet Epidemiol 9: 141–154